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Signal transduction via nuclear hormone receptors is unusual 
in that the hormone ligand forms an integral part of the protein 
complex involved in DNA binding and transcriptional 
activation. New structural and biochemical results have begun 
to unravel how these receptors produce different effects in 
different cells, and the structural changes involved in 
transcriptional activation. 
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Introduction 
Radiolabeled steroid and thyroid hormones of high specific 
activity were first prepared in the late 1960’s, and were 
used as probes to identify the sites of hormone action [l]. 
It has been known for nearly 30 years that these hormones 
act via intracellular receptor proteins whose principal target 
for action is in the nucleus. The receptor proteins were 
quickly surmised to be regulators of transcription [Z-6], 
and are now known to be part of the nuclear receptor 
superfamily. This large group of transcription factors 
includes proteins that mediate the action of the steroid 
hormones (such as estrogens, androgens, glucocorticoids, 
mineralocorticoids and the insect steroid hormone 
ecdysone), as well as the non-steroid hormones (for 
example, thyroid hormone, vitamin D3 and the retinoids) 
and receptors that mediate the peroxisomal proliferation 
response to fatty acids and other factors (Fig. 1) [7-111. 
Many other members of the superfamily have been identi- 
fied by low stringency hybridization analysis; some of the 
genes thus identified encode proteins that are known to 
be expressed and have the conserved six-domain structure 
seen in the hormone receptors. Because the hormonal 
ligands for these proteins are unknown, they are termed 
‘orphan’ receptors [12]. It is however possible that some of 
these so-called receptors may act as transcription factors 
alone, without ligands. To add to the complexity of the 
situation, most classes of receptors within this family 
contain more than one subtype (i.e., products of closely 
related genes); sometimes there are also different isoforms 
(i.e., products from alternate transcription start sites on the 
same gene) and products of mRNA splice variants. Both 
the concentration of these receptors and the relative ratio 
of subtypes and isoforms vary in different target tissues 
and at different stages of development. 
Structure and function of the nuclear receptors 
The signature of the nuclear receptor family is a six- 
domain structure, the most highly conserved portion of 
which is the small (-7040 amino acids) domain, C, that is 
responsible for DNA binding (Fig. 2). This domain has 
been known for some time to have a helix-loop-helix 
structure containing two zinc atoms, each chelated by four 
cysteine thiols at the start of each helix. Three residues at 
the start of the first helix in this domain ‘read’ a five to six 
base pair code in a DNA hormone-response element; the 
mechanism of this sequence-specific recognition is 
becoming increasingly clear through structural analysis of 
domain C-oligonucleotide complexes by X-ray crystallog- 
raphy [13]. The large (-250 amino acid) domain, E, which 
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Figure 1 
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Structures of nuclear receptors and their ligands. (a) Common domain 
structure of representative members of the nuclear receptor 
superfamily, human estrogen receptor o (hERa), human glucocorticoid 
receptor o (hGRu), human thyroid hormone receptor (hTRa,), human 
retinoic acid receptor y (hRARy), and two orphan receptors COUP-TF 
and HNF-4. The DNA-binding domain C and ligand-binding domain E 
are shown with their percent sequence identity (or similarity, in 
parentheses) to hERo. (b) The natural ligands for the first four 
receptors in (a) are shown; there are no known ligands for the orphan 
receptors COUP-TF and HNF-4. 
is moderately conserved across members of the family, is 
responsible for hormone binding and dimerization, and is 
critical in the regulation of transcription (see below). The 
other domains (the amino-terminal A/B domains, the 
hinge domain D, and sometimes a carboxy-terminal 
domain, F), which are poorly conserved in length and 
sequence across the family, are mostly involved in the 
modulation of receptor function. 
Nuclear receptor ligands are directly involved in 
transcriptional regulation 
Recent advances have clarified the various ways in which 
these nuclear receptors can become activated, as well as 
some of the molecular details of the modulation of the 
transcriptional activity of specific genes. The essential 
and intricate role of the ligand in controlling the regula- 
tion of gene transcription by these receptors is also now 
becoming clearer (Fig. 3) [ 14,151. Although hormones and 
growth factors that interact with receptors at the cell 
membrane may ultimately affect gene transcription, they 
require multiple-step signal transduction pathways to do 
so (Fig. 3a); the change in transcription factor activity 
takes place far away from the interaction between the 
receptor and the provoking hormonal agent. By contrast, a 
ligand that activates a nuclear receptor forms a part of the 
multicomponent complex that directly regulates gene 
transcription. Such direct interactions offer interesting 
opportunities for selective pharmacology [ 161. 
There is evidence that high affinity binders for steroid 
hormones exist in cell membranes, especially in some 
brain, pituitary and cancer cells. These receptors appear to 
mediate some very rapid effects of steroid hormones, and 
it is not yet clear whether their modes of action are similar 
to or different from the nuclear receptors [17,18]. We will 
focus here exclusively on the nuclear receptors, since the 
information on this class is most complete. 
Variations on a theme 
The classical picture of gene activation via nuclear recep- 
tors (Fig. 3b) is straightforward. The hormonal ligand 
binds to the receptor; the receptor-ligand complex thus 
formed binds (usually as a dimer) to a hormone-response 
element in the promoter region of a regulated gene, and 
the transcription of the gene connected to the promoter is 
thus activated. 
Figure 2 
A ribbon structure representation of the human glucocorticoid 
receptor DNA-binding domain dimer complexed with a glucocorticoid 
response element (GRE). The DNA contact helices, shown edge on, 
interact with the palandromic DNA sequences of the GRE in adjacent 
major grooves. 
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Figure 3 
Both membrane receptors and nuclear 
receptors modulate gene transcription, but 
nuclear receptors do so more directly. (a) 
Membrane receptor signaling; (b) nuclear 
receptor signaling. In a membrane receptor 
signaling system, the signal resulting from the 
binding of the ligand (L) to the receptor must 
be transduced to the nucleus via complex 
signal-transduction cascades, which typically 
involve second messengers, kinase cascades 
and/or phosphorylation (P) of intermediary 
proteins (such as STATS) in the cytoplasm. 
The end result is a change in the activity of a 
transcription factor (TF) in the nucleus, 
affecting the rate of initiation of RNA 
polymerase II (pal II). The effects of a 
hormone that acts via a nuclear receptor are 
much more direct; the ligand and receptor 
form part of the multicomponent complex that 
modulates pol II activity. 
It cannot, however, be this simple. The target of the 
ligand-receptor complex can clearly vary with cell type, 
which would be impossible in the rudimentary scheme 
described above. For example, when estrogen binds to the 
estrogen receptor in breast cancer and uterine cells the 
result is the stimulation of transcription from some early 
response genes, such as c-myc, and genes for growth factors 
(such as TGF-a or pS2) or growth factor receptors (such as 
the EGF receptor) that are involved in the stimulation of 
cell proliferation evoked by the hormone [19]. The same 
Figure 4 
The subcellular location of unliganded 
nuclear receptors affects the way that they 
modulate transcription. (a) The unliganded 
receptors for nonsteroid ligands such as 
thyroid hormone and retinoic acid are 
typically bound as dimers to their hormone 
response elements (HREs), even in the 
absence of ligand, and can act as 
transcriptional repressors without ligands or 
transcriptional activators with ligand. (b) The 
unliganded receptors for some steroid 
hormones, such as glucocorticoids, are 
largely held as monomers in the cytoplasm by 
heat-shock proteins (90, 23), chaperonins 
(70) and immunophilins (40, 52, 54); in this 
state they have no effect on transcription. 
Ligand binding releases the receptors from 
the cytoplasmic aggregate, and the activated 
receptors bind as dimers to the HREs and 
activate transcription. 
ligand-binding event in pituitary and liver cells results in 
activation of other genes. In the pituitary, the expression of 
various secreted proteins such as prolactin is increased, 
whereas in the liver the level of vitellogenin, among others, 
is increased. 
The variations on the classical picture occur at all levels. 
One source of variability in the effect of ligand binding is 
the cellular distribution of the receptor in the absence of 
ligand. The receptors for certain non-steroid ligands (e.g., 
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thyroid hormone and the retinoids) appear to be already 
bound to their response elements (Fig. 4) [ZO]. Ligand 
binding may strengthen DNA binding, and may alter the 
structure of the receptor so as to enhance transcription 
(see below). In the absence of ligand, these DNA-bound 
receptors repress gene transcriptional activity [21,22]. In 
contrast, many of the steroid nuclear receptors (e.g., the 
glucocorticoid receptor) are largely cytoplasmic in the 
absence of ligand. They are held in the cytoplasm in 
complex with heat-shock proteins, chaperonins, and 
various other proteins such as immunophilins [23]. Ligand 
binding helps the receptor to shed these proteins, move 
into the nucleus, dimerize, and interact with appropriate 
hormone response elements (Fig. 4). In such a scheme, 
the unliganded receptor cannot be used as a transcrip- 
tional repressor, as it is held in the cytoplasm, away from 
the DNA. The degree of nuclear versus cytoplasmic local- 
ization of unliganded receptors varies with different recep- 
tors and in different cells, so the effect of the unliganded 
receptor on transcription will depend on the cell and 
response in question. 
A second level of variation in our originally simple scheme 
is the way in which the receptor forms a dimer. The non- 
steroid nuclear receptors for thyroid hormone, vitamin D 
and retinoic acid can either form homodimers or hetero- 
dimerize with the retinoid X receptor [12,20]. The recep- 
tor for the insect steroid hormone ecdysone, on the other 
hand, is active only as a heterodimer with the protein 
ultraspiracle, a homolog of the retinoid X receptor (RXR). 
The preference of the thyroid, vitamin D and retinoic acid 
receptors for pairing with themselves or with another 
partner depends on several factors, including the relative 
concentration of the monomer components (not forgetting 
the different subtypes and isoforms) and of their cognate 
ligands. Ligand binding can, in some situations, modulate 
the formation of specific complexes [24]. A further factor 
is the structure of the DNA response elements with which 
the homo- or heterodimers interact [20,24]. 
The dimerization of steroid receptors at first appeared to 
be less complicated, since heterodimerization between 
receptors that bind different ligands (like the thyroid 
Variations also occur at a third level, the interaction of 
nuclear receptors with the DNA response elements. 
Although the response elements are often portrayed as con- 
sensus sequences - inverted or direct repeats of a defined 
five- to six-nucleotide sequence, with various spacers 
between the repeats - the response elements found in 
responsive genes are often nonconsensus in sequence; some 
are half-sites and others have multiple repeats. Often the 
response elements are found in complex, upstream- 
enhancer regions, clustered together or even overlapping 
with response elements for other known transcription 
factors, which may synergize or compete with the nuclear 
receptors. Sequences that flank the core response elements 
can also affect the DNA binding of these receptors (see, for 
example, [29]). And the structure of the DNA response 
element, since it affects the recognition between the recep- 
tor and the DNA, may also affect the interaction between 
the receptor and the ligand. 
Given all the sources of variation described above, espe- 
cially the fact that nuclear receptors may interact with or 
compete with a number of other sequence-specific trans- 
cription factors, it is not surprising that the response to a 
specific hormone depends on both the cell in which it is 
acting and the gene whose activity it modulates [16]. 
Nuclear receptor activation without direct DNA binding or 
without ligand binding 
A curious but major deviation from the classical scheme 
for nuclear receptor action is gene activation in the 
absence of direct DNA-binding by the receptor. In this 
situation the promoter for a gene whose activity is clearly 
regulated by a nuclear receptor and its hormone appears to 
have no hormone-response element for the receptor, and 
does not, in fact, require direct DNA binding by the 
receptor. The hormone-receptor complex seems to func- 
tion by binding to DNA indirectly via other DNA-teth- 
ered transcription factors (see, for example, [30-321) thus 
acting as a ligand-modulated co-regulator, rather than a 
ligand-modulated transcription factor (Fig. 5). 
Figure 5 
Receptor dimerization and receptor stability are impor- Nuclear receptor gene activation can occur without direct DNA 
tant points for pharmaceutical regulation of transcription binding. The nuclear receptor is tethered to DNA by a protein-protein 
via nuclear receptors, and several hormone antagonists interaction with another sequence-specific transcription factor,.such as 
(some antiestrogens and antiprogestins, for example) fos/jun (APl). In such a case, the nuclear receptor has the role of a 
appear to act at this level [ZS-281. 
ligand-modulated co-activator of transcription. 
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Figure 6 
Co-regulators mediate the interaction 
between the nuclear receptor and 
components of the transcription complex. 
Unoccupied or antagonist-occupied 
receptors can recruit co-repressors (left); 
when an agonist ligand binds, the 
ligand-receptor complex can recruit co- 
activators (right). 
Agonist-occupied 
Another major deviation from the classical scheme for acti- 
vation of genes by nuclear receptors is ligand-independent 
gene activation. In certain systems there appears to be sig- 
nificant crosstalk between signal-transduction pathways 
that activate transcription. The result is that growth factors 
or hormones that operate through receptor tyrosine 
kinases or via CAMP or other second messengers can acti- 
vate nuclear receptor regulated genes in a manner that 
requires receptor but not ligand [19]. In some cases, these 
alternative pathways may synergize with the normal ligand- 
mediated pathway [33]. The molecular mechanism for 
such action is not well understood, but it is possible that 
phosphorylation of specific sites on the nuclear receptors 
may enhance the transcriptional activity of the unliganded 
receptor [19,34]. 
Modulation of gene transcription 
Once a nuclear receptor is bound to DNA, what happens 
next? The final step of the classical pathway, the process 
by which these receptors modulate the rate of gene trans- 
cription (Fig. 6), has its own sources of regulatory com- 
plexity. First, it is important to recognize that the rate at 
which a gene is transcribed depends both on the local 
chromatin architecture, and on the rate at which an active 
RNA polymerase preinitiation complex can be assembled. 
The nuclear receptors appear to affect both of these 
processes, both directly and indirectly via ‘transcription 
intermediary factors’ (TIFs) [9,35,36], although their 
effect on chromatin architecture is poorly understood. 
There is evidence that DNA-bound nuclear receptors 
interact directly with some of the proteins comprising the 
basal transcription machinery, such as TFIIB or TATA- 
binding protein associated factors (TAFs) [37-391. If they 
suppress or stimulate a rate-limiting step in the assembly 
of an active RNA polymerase II preinitiation complex, this 
would result in repression or activation of transcription. In 
many cases the relevant interactions between nuclear 
receptors and basal transcription factors appear not to be 
direct, however, but are mediated by various co-regulators. 
The co-regulators involved in nuclear-receptor modula- 
tion of gene transcription are diverse, and are being dis- 
covered at an increasing rate. They are often large 
multidomain proteins, with some homology to factors that 
are known to modulate chromatin structure; some have 
known protein-interaction domains, or have the ability to 
interact with various components in the general transcrip- 
tion apparatus [16]. Some also appear to fit nicely into the 
unliganded-repression/liganded-activation paradigm, in 
that one set of co-regulators binds to the unliganded 
thyroid and retinoid receptors to repress transcription 
[40,41], whereas another set binds to liganded receptor to 
enhance transcription [42-46]. In the case of the steroid 
receptors, the co-regulators appear to bind to either the 
amino-terminal or carboxy-terminal activation domain of 
the receptors. Some co-regulators interact with and influ- 
ence the transcriptional activity of many steroid hormone 
receptors and other related receptors, such as RXR, 
whereas other co-regulators show a more restricted range 
of receptor interaction. 
Structural and conformational changes on ligand binding 
As the interaction between the co-regulators and the 
nuclear receptor is regulated by ligand binding, it is plausi- 
ble that ligand binding elicits a conformational change in 
the receptor that may permit co-activator but not co-repres- 
sor binding in the presence of ligand (or co-repressor but 
not co-activator binding in the absence of ligand). Muta- 
tional mapping studies have begun to identify the different 
regions of the receptor that seem to be responsible for 
interaction with co-repressors and co-activators [35,43,47]. 
Most exciting are some of the structural features revealed 
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Figure 7 
Stereoview of a ribbon structure of the 
ligand-binding domain of the rat thyroid 
hormone receptor complexed with thyroid 
hormone (T3), shown as a skeletal structure 
in the lower half of the protein. The regions of 
a-helical (H) and p-strand (S) secondary 
structure are designated. 
in the recent X-ray crystal structures of three different 
receptor ligand-binding domains (domain E) (Fig. 7); 
these structures provide insight into the conformational 
reorganization that occurs upon ligand binding [48-511. 
The ligand-binding domain of the nuclear receptors is 
large, larger than most single protein domains, with a 
unique antiparallel a-helix triple sandwich topology 
(Fig. 7). Approximately half of the domain consists of a 
rigid, tightly packed assembly of helices that appear to act 
as a fundament or fulcrum for the action of the remainder of 
the domain, which is more flexible and is involved in ligand 
binding. Although the three structures that have been 
described so far do not permit a direct comparison between 
the conformations of a single receptor in the liganded and 
unliganded state, certain general features have emerged that 
are likely to hold true for the ligand-induced conformational 
changes of all of the members of the superfamily. 
In the bound state, the ligand is completely engulfed by the 
flexible portion of the domain, and actually forms the 
hydrophobic core for this region [49,50]. Six segments of 
secondary structure, arranged roughly as the six sides of a 
box, surround the ligand, with more than 20 residues 
making direct contact with the ligand (Fig. 8). In the lig- 
anded state, the carboxy-terminal portion of this domain, an 
amphipathic helix, termed the activation function 2 activa- 
tion domain (AFZ-AD), interacts with the ligand and is posi- 
tioned adjacent to two other helical portions of the receptor 
whose specific orientation is also dependent upon contacts 
with the ligand (see Fig. 7, helix 12). This composite 
surface, whose integrity appears to be critically dependent 
on ligand binding, is one likely site for co-activator binding. 
By contrast, in the unbound state, the flexible portion of 
the ligand-binding domain lacks its hydrophobic core, 
namely, the ligand. In the one published structure for an 
unliganded receptor [48], the box-like structure of the 
flexible portion of domain E appears to have collapsed, 
with two sides tipping inward and two sides tipping 
outward; the activation helix is dislodged from its position 
between the other two helices, since their relative position 
is no longer supported by contacts with the ligand (see 
Fig. 8). The composite surface for co-activator binding is 
thus absent or at least substantially modified in the unli- 
ganded state. But in the collapsed state, various new topo- 
graphical features have developed, providing potential 
sites for co-repressor binding. 
X-ray crystallography provides static pictures of protein 
structure. It is thus possible that the flexible ligand- 
binding region of domain E in the unliganded state may 
be rather fluid, perhaps in a molten globule-like state. 
The binding of heat shock proteins (which normally bind 
only to unfolded or partially folded proteins) and 
immunophilins to the unliganded steroid receptors and 
the sensitivity of the unliganded receptor to proteolysis 
supports this view [SZ]. Further studies, especially ones 
in which a direct comparison can be made between struc- 
tures of the liganded and unliganded state of the same 
receptor, will be needed to verify the generality of these 
conformational transitions. 
Ligand binding affects receptor shape - thus, receptor 
shape reflects ligand shape. As co-repressor/co-activator 
binding responds to alterations in receptor shape, the 
ligand is the crucial factor in recruiting or disbanding these 
important co-regulators. The view that ligand shape deter- 
mines receptor shape and thus receptor activity can also 
account for the spectrum of biological activity - from pure 
agonists to partial agonists/antagonists to pure antagonists 
- that is known for ligands for some of these nuclear 
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Figure 8 
A ‘box model’ for the ligand-binding domain 
of a nuclear receptor. When an agonist 
ligand is bound, the upper box, made up of 
mobile segments with the ligand at its core, 
is ‘filled’; in this conformation, it has a 
structure in which the activation domain (helix 
12) is in the active state, where it can interact 
with co-activators, activating transcription. 
Without ligand, the upper box is empty and is 
‘crushed’, so that two sides cave inward and 
two sides bulge outward; the activation helix 
is displaced from the active state, and the 
empty receptor is thus either inactive or 
recruits co-repressors to become repressive. 
Antagonists and partial agonists fill the top 
box in a different manner, such that the 
activation helix is fully or partially misoriented 
from the activating position. The 
conformation of the lower box is not affected 
by ligand binding. (Note that this schematic 
representation of the ligand binding domain 
of a nuclear receptor is shown in the 
orientation opposite to that of the thyroid 
hormone receptor-T3 complex shown in 
Figure 7. In Figure 7, the ligand-binding ‘box’ 
is at the bottom.) 
receptors, such as estrogens and progestins. Given all this, 
the potential for pharmaceutical modulation of the trans- 
criptional activity of nuclear receptors is obvious [l&16]. 
Pharmacological issues, however, extend beyond the 
ligand-receptor interaction. The biological effect that a par- 
ticular ligand will have, acting via a given receptor, will also 
depend on the intracellular context (i.e., the levels of the 
relevant co-regulators and transcription factors with which 
the receptor cooperates) and the promoter for the specific 
gene being regulated (i.e., the structure of the hormone- 
response element and whether any other transcription 
factors bind to nearby sites). This ‘tripartite receptor phar- 
macology’, comprising ligands, receptors, and cell and 
promoter specific transcriptional effecters, offers rich 
possibilities for developing tissue- and response-specific 
pharmaceuticals [ 161. 
The future 
There is much more to learn. The details of the ligand- 
induced conformational changes within one receptor 
protein are yet to be revealed, and we do not yet know 
how all the different domains of a nuclear receptor interact 
with each other. A full appreciation of the molecular inter- 
actions involved in the gene-regulating action of the 
nuclear receptors will require reconstitution of multipro- 
tein complexes involving the intact receptor (as a homo- or 
heterodimer) interacting with a complete gene regulatory 
region, together with other associated transcription factors, 
co-regulator proteins, and elements of the general trans- 
cription apparatus. Equally important will be biological 
studies detailing regulation of the levels and activity of 
receptors and their co-regulators as a function of physio- 
logical and developmental state in different hormonal 
target cells and tissues. Clearly, the major and perhaps the 
most exciting challenges still lie ahead. 
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